beLean.net is a Health+Digital accelerator providing services in strategy, finance and management
The pillars of our long-term relationship
01. Business Strategy
We support successful transformation and commercialization
02. Corporate Finance
We support business modelling and finance management
03. Subsidies & Funding
We support assets valuation and empower healthcare innovation
04. Expertise & Networking
We support Health Economics, Research Strategy and Funding Canvas
05. Compliance & Governance
We support standards of compliance in controlling process
beLean.net is the reference accelerator in the field of health biotechnology and medical technologies in Wallonia (Belgium) and aims to transform all the challenges linked to digital transformation into opportunities.
Our strategic vision is to share our expertise to support start-ups all along their journey, by structuring their ecosystems to better respond to the new challenges of today and tomorrow:HEALTH DIGITAL
We help you modelling your idea
We help you build or develop your MVP – “minimum viable product”
We help you determine whether real progress is being made or not
We help you make decisions based on the measurements accumulated
We are a team of complementary experts to support your development
Guillaume de Viron
Elodie Verlaine Kouwe
WE ARE CERTIFIED BY WALLOON REGION
Benefit from financial assistance up to 80%
- Market Identification, Technical & IP Review
- Go/No-Go Decision
- Work Environment Co-creation
- Business Creation
- FFF & Subsidies
- Market Diagnosis
- Business Modelling
- Business & Finance Plan
- Assets Valuation
- Seed Funding & Subsidies
We would be pleased to consider your project and find together the best suitable solution dedicated to your needs
Our latest internal and customer news
Cliquez ici pour télécharger gratuitement notre guide de survie des start-ups face à la crise du COVID-19. Les nouvelles et le stress associés au COVID-19 dans le monde entier créent le doute, l’incertitude et l’anxiété parmi les dirigeants, les employés et les clients. Au-delà des mesures de bon sens prises par le gouvernement, nous voulons, chez beLean.net,[…]
Savics is collaborating since more than 2 weeks with KU Leuven and DNAlytics to collect, gather and analyze COVID-19 test results. DataToCare COVID-19 is/will be used by all 7 University Laboratories across Belgium that support and unload the Belgian COVID-19 Reference Laboratory from UZ Leuven. DataToCare COVID-19 is a software installed in laboratories that capture COVID-19 test results and[…]
With the novel coronavirus continuing its global spread, drugmakers are pouring massive resources into developing targeted therapies and vaccines. Now, a new CDMO from Belgium’s Univercells is hoping its expertise can help drugmakers scale up their manufacturing for a successful shot. Univercells has launched Exothera, a viral vector CDMO targeting cell and gene therapy and vaccine developers, in a refurbished 15,000-square-meter[…]
PDC*line Pharma announces the administration of a first patient with its therapeutic cancer vaccine candidate targeting non-small cell lung cancer
Liège, Belgium and Grenoble, France, March 3, 2020 – PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces today that the first patient was dosed with its innovative medicinal product candidate PDC*lung01 in a phase I/II trial in non-small cell lung cancer (NSCLC). This patient is under[…]
BRUSSELS, BELGIUM – FEBRUARY 18,2020 — Univercells, an innovative bioprocessing provider focused on increasing the availability of affordable biologics to address global health challenges, has announced up to EUR 50M financing from Gamma Biosciences, a new investment platform supported by leading global investment firm KKR, that is focused on next-generation bioprocessing technologies for the production of advanced[…]
GOSSELIES, BELGIUM – FEBRUARY 14TH, 2020 — OncoDNA (“OncoDNA or “the Company”), the healthcare technology company making precision medicine a reality, today announced that it has completed a €19 million ($20 million) Series B equity financing. The new funding will support rapid international growth, accelerate software development and hiring initiatives. The round was led by Vesalius Biocapital[…]
GOSSELIES, BELGIUM – February 3, 2020 — MaSTherCell S.A., a subsidiary of MaSTherCell Global, Inc., a subsidiary of Orgenesis Inc. (NASDQ: ORGS) a technology-focused cell and gene therapy contract development and manufacturing partner to leading cell therapy innovators, today announced an agreement to acquire MaSTherCell Global that has been reached between the owners of MaSTherCell Global and Catalent Pharma[…]
Check the latest issue of Biotech Finances to read an interview of PDC*line Pharma’s President & CEO Eric Halioua describing the recent fund raising completed and the perspectives of the company. Source: https://www.biotech-finances.com/126504-2/
Liège, Belgium and Grenoble, France, January 22, 2020 – PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces today the completion of its Series B round of financing. The company has raised a total of €20 million ($22.2M). Two and a half years after its last round of[…]
We took part in the event “Anchoring Clinical Research in Belgium” jointly organized by BioWin and flanders.bio in Brussels where we had an interesting debate on funding opportunities for biomedical research and clinical trials development in a sector where Belgium is leading globally. Thank you to Bone Therapeutics, icometrix and Ayming Belgium for sharing the stage.
A new article about our customer PDC*line Pharma published in the newspaper L’Echo: with an interview of President & CEO Eric Halioua underlining the achievements made by the company over the last 4 years. Source: https://www.lecho.be/entreprises/pharma-biotechnologie/PDC-line-Pharma-nouvel-espoir-wallon-contre-le-cancer/10191614
“How will LegalTech sensitize start-ups to good governance?” We gave some answers at the Legal & Tech Summit organized by Reshape.legal in Brussels.
Proud to have been selected to introduce Digiboard – our digital board compliance solution – at Web Summit 2019 in Lisbon, the world’s largest tech event.
Digiboard will be in demo at the Walloon innovations fair on October 24 at Espace Magnum (Colfontaine). Link: https://www.innovationswallonnes.be/fr/innovations/une-solution-de-digitalisation-pour-les-conseils-dadministration#no-back
We have been selected to present Digiboard at Legal & Tech Connect 2019, the place where LegalTech startups, customers and investors meet. Link: https://www.reshape.legal/ltconnect.html
Our customer Imcyse is announcing to the world their excellent first-in-human clinical results in Type 1 Diabetes. Imcyse reports successful first-in-human Phase 1b study in type 1 diabetes with IMCY-0098
Proud to have helped Imcyse to fundraise 35M€ to carry out clinical trials of treatments for type 1 diabetes, multiple sclerosis and other autoimmune diseases. Please read the article in L’Echo: https://www.lecho.be/entreprises/pharma-biotechnologie/imcyse-se-profile-comme-la-future-pepite-wallonne-de-la-biotech/10137301.html Imcyse secures total of €35M in Series B financing round and additional grants
We are present at BioWinConnect 2018 to get last updates about incubation models and collaboration that could enforce our startup studio.
B.R.A.I.N. hub (Belgian Research And Innovation in Neurosciences), the second European Human Brain Project’s National Hub for Innovation (HBP-NHI-be), was successfully launched in Belgium thanks to the initiative of Abaxys Therapeutics and our startupstudio.be. Press release: https://gallery.mailchimp.com/86270bb6b0c29cba9301c4907/files/d77b9722-7fd0-4679-9ef4-18cd08f24a6f/BRAINhub_kick_off_press_release_HBP_NHI_be_Mar_2019.pdf?mc_cid=27e3a48b74&mc_eid=6d7be67224
PDC*line Pharma enters into a licensing agreement with leading Korean pharmaceutical company LG Chem
New success story for our customer PDC*line Pharma which enters into a licensing agreement with leading Korean pharmaceutical company LG Chem to develop PDC*lung cancer vaccine in Asia. PDC*line Pharma enters into licensing agreement with LG Chem to develop PDC*lung cancer vaccine in Asia
Any questions on business creation, dilutive and non-dilutive funding? We will be pleased to freely advise you at the upcoming MedTech Meetup 2019. Book your 10-minute face-to-face meeting now!
beLeant.net and Digiboard.io are present at SHAKE Digital Wallonia 2018 to get last updates about disruptive innovations.
We are pleased to announce the launch of beLean.net’s new logo as part of the ongoing evolution of our company’s brand. More details: https://mailchi.mp/573556897c45/new-logo-announcement
Ready to support our new customers with our international partners. Meeting up with Ventor.tech at the last edition of Odoo Experience.
Proud to have supported a third of the biotech companies which are representing Belgium at BIO-Europe 2017 in Berlin, Europe’s largest life science partnering conference.
Our customer Univercells has been awarded a $12 Million grant by the Bill & Melinda Gates Foundation to develop a breakthrough vaccine manufacturing platform. Its aim is to drastically reduce the cost of vaccines whilst increasing their availability and affordability in developing countries. « Humanity’s greatest advances are not in its discoveries, but in how those discoveries[…]
The Deloitte Technology Fast 50 competition is an annual selection of the 50 fastest-growing technology companies within Belgium. The initiative is designed to encourage and promote entrepreneurial, fast-growing technology companies. On Wednesday 19th of November 2015, OncoDNA was named “Most Disruptive Innovator” in the Rising Star category. This award recognises companies that have developed a[…]
Our customer Univercells partners with Takeda Pharmaceutical Company Limited to produce affordable vaccines for All. Press release: http://www.univercells.com/newsroom/univercells-partners-takeda/
Through a reversible deal, MaSTherCell has been acquired by Orgenesis (a leader in the emerging fields of cellular therapy and re-generative medicine for the treatment of Type 1 Diabetes) in March 2015. MaSTherCell will be responsible for the development and the commercialization of Orgenesis’ product and will also maintain his CDMO core business activity in[…]